Metabolic and Bariatric Surgery and Obesity Pharmacotherapy for Cancer Prevention: Current Status and Future Possibilities

Overview

Journal J Natl Cancer Inst Monogr

Publisher Oxford University Press

Specialty Oncology

Date 2023 May 4

PMID 37139980

Authors

Mary C Playdon

Sheetal Hardikar

Prasoona Karra

Rachel Hoobler

Anna R Ibele

Katherine L Cook

Amanika Kumar

Joseph E Ippolito

Justin C Brown

Affiliations

Soon will be listed here.

Abstract

Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.

References

Ward Z, Long M, Resch S, Giles C, Cradock A, Gortmaker S . Simulation of Growth Trajectories of Childhood Obesity into Adulthood. N Engl J Med. 2017; 377(22):2145-2153. PMC: 9036858. DOI: 10.1056/NEJMoa1703860. View

Muller T, Bluher M, Tschop M, DiMarchi R . Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2021; 21(3):201-223. PMC: 8609996. DOI: 10.1038/s41573-021-00337-8. View

Srivastava G, Apovian C . Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2017; 14(1):12-24. DOI: 10.1038/nrendo.2017.122. View

Schmitz K, Gehlert S, Patterson R, Colditz G, Chavarro J, Hu F . TREC to WHERE? Transdisciplinary Research on Energetics and Cancer. Clin Cancer Res. 2016; 22(7):1565-71. PMC: 4956346. DOI: 10.1158/1078-0432.CCR-14-1214. View

Zhang K, Luo Y, Dai H, Deng Z . Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis. Obes Surg. 2019; 30(4):1265-1272. DOI: 10.1007/s11695-019-04368-4. View

Lovrics O, Butt J, Lee Y, Lovrics P, Boudreau V, Anvari M . The effect of bariatric surgery on breast cancer incidence and characteristics: A meta-analysis and systematic review. Am J Surg. 2021; 222(4):715-722. DOI: 10.1016/j.amjsurg.2021.03.016. View

Tao W, Santoni G, von Euler-Chelpin M, Ljung R, Lynge E, Pukkala E . Cancer Risk After Bariatric Surgery in a Cohort Study from the Five Nordic Countries. Obes Surg. 2020; 30(10):3761-3767. PMC: 7467909. DOI: 10.1007/s11695-020-04751-6. View

Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L . Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020; 383(11):1000-1002. DOI: 10.1056/NEJMp2003873. View

Kauppila J, Tao W, Santoni G, von Euler-Chelpin M, Lynge E, Tryggvadottir L . Effects of Obesity Surgery on Overall and Disease-Specific Mortality in a 5-Country Population-Based Study. Gastroenterology. 2019; 157(1):119-127.e1. DOI: 10.1053/j.gastro.2019.03.048. View

10.

OMeara S, Riemsma R, Shirran L, Mather L, Riet G . A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004; 5(1):51-68. DOI: 10.1111/j.1467-789x.2004.00125.x. View

11.

Parker E, Folsom A . Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study. Int J Obes Relat Metab Disord. 2003; 27(12):1447-52. DOI: 10.1038/sj.ijo.0802437. View

12.

Heck A, Yanovski J, Calis K . Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000; 20(3):270-9. PMC: 6145169. DOI: 10.1592/phco.20.4.270.34882. View

13.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

14.

Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4. View

15.

Casagrande D, Dornelles Rosa D, Umpierre D, Sarmento R, Rodrigues C, Schaan B . Incidence of cancer following bariatric surgery: systematic review and meta-analysis. Obes Surg. 2014; 24(9):1499-509. DOI: 10.1007/s11695-014-1276-0. View

16.

Droney A, Sellers W, Gupta A, Johnson K, Fluck M, Petrick A . Incidence of polyp formation following bariatric surgery. Surg Obes Relat Dis. 2021; 17(10):1773-1779. DOI: 10.1016/j.soard.2021.06.005. View

17.

Eisenberg D, Shikora S, Aarts E, Aminian A, Angrisani L, Cohen R . 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022; 18(12):1345-1356. DOI: 10.1016/j.soard.2022.08.013. View

18.

Luo J, Hendryx M, Manson J, Figueiredo J, LeBlanc E, Barrington W . Intentional Weight Loss and Obesity-Related Cancer Risk. JNCI Cancer Spectr. 2019; 3(4):pkz054. PMC: 6795232. DOI: 10.1093/jncics/pkz054. View

19.

Hussan H, Akinyeye S, Mihaylova M, McLaughlin E, Chiang C, Clinton S . Colorectal Cancer Risk Is Impacted by Sex and Type of Surgery After Bariatric Surgery. Obes Surg. 2022; 32(9):2880-2890. DOI: 10.1007/s11695-022-06155-0. View

20.

Garcia S, Barros L, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A . The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2005; 240(2):221-4. DOI: 10.1016/j.canlet.2005.09.011. View